Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Badi (London, United Kingdom), A. Pavel (New York, United States of America), J. Riley (Stevenage, United Kingdom), K. Chung (London, United Kingdom), E. Guttman-Yassky (New York, United States of America), I. Adcock (London, United Kingdom). Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma?. 1606

Member's Comments

No comment yet.

Related content which might interest you: Phase 2, mutlicenter, double-blind study of CNTO 148, a human monoclonal anti-TNF α antibody, in symptomatic patients with severe persistent asthma Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007 Anti-interleukin-13 antibody therapy for asthma: one step closer Source: Eur Respir J 2013; 41: 255-256 Year: 2013 A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study Source: Eur Respir J 2007; 30: Suppl. 51, 622s Year: 2007 Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 Antinuclear antibodies and severe evolution of asthma Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Management of severe allergic asthma in the UK: Which monoclonal antibody would you choose? Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease Source: Eur Respir J 2007; 30: 383-390 Year: 2007 Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all? Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease Year: 2020 Two novel, severe asthma phenotypes identified during childhood using a clustering approach Source: Eur Respir J 2012; 40: 55-60 Year: 2012 A monoclonal antibody to IL-1B attenuates the late asthmatic response to antigen challenge in patients with mild asthma Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006